Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

antibody-drug conjugate 3

Home Drugsantibody-drug conjugate 3

antibody-drug conjugate 3

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1/TIM-3 BISPECIFIC BINDING PROTEIN
Applicant: ASTRAZENECA UK LTDPriority: 2023
CN
EP
WO
3 publications
DOSING REGIMENS OF ANTIBODY-DRUG CONJUGATE TARGETING DELTA-LIKE LIGAND 3 FOR TREATMENT OF NEUROENDOCRINE NEOPLASMS
Applicant: ZAI LAB SHANGHAI CO LTDPriority: 2024
WO
DOSING REGIMENS OF ANTIBODY-DRUG CONJUGATE TARGETING DELTA-LIKE LIGAND 3 FOR TREATMENT OF NEUROENDOCRINE NEOPLASMS
Applicant: ZAI LAB SHANGHAI CO LTDPriority: 2024
WO
Antibody-drug complex containing toll-like receptor 7/8 dual agonist compound
Applicant: ASTELLAS PHARMA INCPriority: 2022
US
2 publications
Ligand-drug conjugate, preparation method and medical application thereof
Applicant: SHANGHAI HANSOH BIOMEDICAL CO LTDPriority: 2021
CN
METHOD FOR CONTINUOUSLY PREPARING ANTIBODY-DRUG CONJUGATE
Applicant: WUXI XDC SHANGHAI CO LTDPriority: 2025
WO
ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Applicant: SHANGHAI HUAOTA BIOPHARMACEUTICAL CO LTDPriority: 2022
CN
EP
US
WO
4 publications
COMBINATION OF (ANTI-HER3 ANTIBODY)-DRUG CONJUGATE AND RASG12C INHIBITOR
Applicant: DAIICHI SANKYO CO LTDPriority: 2023
EP